|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in the BRCA1 and BRCA2 genes predispose carriers to breast and ovarian cancer, and there remains a need to identify the specific genomic mechanisms by which cancer evolves in these patients.
|
31182087 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
BRCA1 or BRCA2 inactivation drives breast and ovarian cancer but also creates vulnerability to poly(ADP-ribose) polymerase (PARP) inhibitors.
|
30686591 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Epithelial ovarian cancer is composed of distinct histological subtypes with unique genomic characteristics, which are improving the precision and effectiveness of therapy, allowing discovery of predictors of response such as mutations in breast cancer susceptibility genes BRCA1 and BRCA2, and homologous recombination deficiency for DNA damage response pathway inhibitors or resistance (cyclin E1).
|
30910306 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
Significant associations with OC were observed in <i>BRCA1, BRCA2, RAD51C</i> and <i>RAD51D.</i> Other homologous recombination genes, <i>BARD1, NBN,</i> and <i>PALB2,</i> were not significantly associated with OC.
|
31341520 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Possible inconsistency in the ratio of BRCA1-to-BRCA2 mutations and the most common mutation between KoOC and KoBC may probably suggest presence of mutation sequence-associated penetrance tendency in hereditary Korean breast and ovarian cancer.
|
30309222 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Nineteen per cent of mutations were recurrent, one of which, BRCA2 c.6024dupG, showed high association to OC.
|
31771539 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
Currently, somatic or germinal mutations on BRCA1 and BRCA2 genes are the most important biomarkers in epithelial ovarian cancer having prognostic and predictive value.
|
28815456 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
After adjusting for mutation position, association between FH and OC risks was slightly smaller in magnitude (HR: 0.85, 95% CI: 0.55-1.30; HR: 0.64, 95% CI: 0.34-1.21 for BC-only FH in BRCA1 and BRCA2, respectively; HR: 1.46, 95% CI: 0.80-2.68; HR: 1.49, 95% CI: 0.44-4.02 for OC-only FH in BRCA1 and BRCA2, respectively), indicating that mutation position explains only part of the association.
|
29483665 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
There were 5712 women tested for a BRCA1 and BRCA2 mutation at the HCP between 2001 and 2014, 887 of which had previously received a diagnosis of ovarian cancer.
|
29506471 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience.
|
29460478 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Among the 1331 patients with OC, 227 (17.1%) carried deleterious variants in BRCA1 and 70 (5.3%) carried deleterious variants in BRCA2.
|
30078507 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Independency of the prognostic value of BRCA2-expression for PFS (P = 0.045) and OS (P = 0.015) was restricted to high-grade serous OCs.
|
30111871 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
For some time, it has been clear that key mutations may be used as both prognostic and predictive biomarkers, the best-known examples being the presence of germline BRCA1 or BRCA2 mutations, which are not only associated with improved prognosis in ovarian cancer, but are also predictive of response to poly(ADP-ribose) polymerase (PARP) inhibitors.
|
29282716 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
The primary aim of this study was to determine which factors influence the intent of individuals with a personal history of breast and/or ovarian cancer and negative or uncertain BRCA1 and BRCA2 testing to return to a hereditary cancer program for additional genetic risk assessment, counseling, and testing.
|
29550970 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Participants had sought genetic testing for a BRCA1 or BRCA2 mutation because of a personal or family history of breast and/or ovarian cancer.
|
29710224 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
Monoallelic inactivation of some FA genes, such as FA complementation group D1 (FANCD1; also known as the breast and ovarian cancer susceptibility gene BRCA2), leads to adult-onset cancer predisposition but does not cause FA, and somatic mutations in FA genes occur in cancers in the general population.
|
29376519 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
Unclassified Variants of BRCA1 and BRCA2 in Korean Patients With Ovarian Cancer.
|
29240602 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The role of both germ line and somatic mutations in BRCA1 and BRCA2 in the development of ovarian cancer is well established, with mutation in either gene resulting in deficiencies in homologous recombination.
|
30092674 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Pathogenic variants in BRCA1 or BRCA2 are identified in ∼20% of families with multiple individuals affected by early-onset breast and/or ovarian cancer.
|
30075112 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
In conclusion, lncRNA RP11-552M11.4 correlates with worse prognosis, and promotes cell proliferation, migration, invasion, and inhibits cell apoptosis by down-regulating BRCA2 in EOC.
|
29478268 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Germline pathogenic mutations in BRCA increase the lifetime risk of developing breast and/or ovarian cancer in women.
|
29297111 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The study aimed to estimate risks of invasive BC and EOC in a large cohort of BRCA1/BRCA2 predictive test negatives.
|
29565421 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
Population-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing can prevent 1.86%/1.91% of BC and 3.2%/4.88% of OC in UK/US women: 657/655 OC cases and 2420/2386 BC cases prevented per million.
|
29361001 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Deleterious mutations in BRCA1 or BRCA2 genes have long been recognized as independent risk factors, mostly for breast and ovarian cancer.
|
29307397 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Women with a BRCA1 or BRCA2 mutation are at increased risk of developing breast and/or ovarian cancer.
|
28382503 |
2018 |